Status:
RECRUITING
Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking
Lead Sponsor:
Washington State University
Conditions:
Alcohol Use Disorder (AUD)
Nicotine Use Disorder
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Using a randomized controlled trial (RCT), the goal of this study is to evaluate the ability of evidence based behavioral treatment (contingency management: CM) to significantly decrease alcohol use a...
Detailed Description
This randomized, placebo-controlled trial to determine the effectiveness of contingency management for reducing alcohol use and cigarette smoking among adults who want to quit or reduce their co-addic...
Eligibility Criteria
Inclusion
- 4 or more standard drinks on the same occasion for women (5 or more standard drinks on the same occasion for men) on at least 4 occasions in the prior 30 days
- Seeking AUD treatment
- Seeking smoking cessation treatment
- Aged 18+ years
- DSM-5 diagnosis of AUD
- Currently smoking daily according to PhenX Smoking Status (100 or more lifetime cigarettes plus current daily smoking)
- Ability to read and speak English
- Ability to provide written informed consent
- Breath alcohol of 0.00 during informed consent
- Provision of at least 1 EtG-positive urine test at any time during the induction period and at least one COT-positive urine test at any time during the induction period; and
- Attended at least 4 of 6 possible visits during the induction period.
Exclusion
- Significant risk of dangerous alcohol withdrawal, defined as a history of alcohol detoxification or seizure in the last 12 months and expression of concern by the participant about dangerous withdrawal
- Currently receiving any pharmacotherapy for alcohol
- Currently receiving any pharmacotherapy for smoking
- No suicide attempt in the last 20 years and
- Any other medical (discernable by initial blood tests) or psychiatric condition that Drs. Layton or Rodin determine would compromise safe participation.
Key Trial Info
Start Date :
July 11 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2026
Estimated Enrollment :
205 Patients enrolled
Trial Details
Trial ID
NCT05181891
Start Date
July 11 2022
End Date
May 1 2026
Last Update
June 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Washington State University
Spokane, Washington, United States, 99202